On Nov. 30, Eisai and Biogen announced the results of their latest phase 3 clinical trial in Alzheimer’s disease. The verdict: an 18-month treatment with lecanemab slows functional and cognitive loss by 27 per cent in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The study results were also published in the New England Journal of Medicine.
The pharmaceutical company Eisai claims that unlike the drugs already approved for Alzheimer’s treatment, this one is able to slow down the disease rather than just reduce its symptoms.
